Teknova (TKNO) Q4 2025 earnings review
Burn Rate Shrinks, But Growth Trajectory Slows as Profitability Target is Pinned to 2027
Teknova delivered a solid end to 2025, beating its cash burn targets and maintaining positive revenue growth. Clinical Solutions staged a massive rebound (+47% YoY), rescuing a quarter where the previously reliable Lab Essentials segment flatlined. However, management's decision to increase commercial investments means Adjusted EBITDA profitability is now explicitly targeted for the end of 2027. With FY26 revenue guidance implying a deceleration to ~6% growth, the company is playing a long game that requires investors to tolerate continued cash burn for at least two more years.
🐂 Bull Case
Clinical Solutions revenue accelerated dramatically to 47% YoY growth in Q4, and the number of Clinical Solutions customers grew 25% for the full year, validating the long-term strategy despite a tough biotech funding environment.
Full-year Free Cash Flow came in at -$9.8M, significantly beating management's prior target of 'less than negative $12 million.' The company is demonstrating operational discipline.
🐻 Bear Case
Lab Essentials, the foundational business representing ~70% of revenue, generated 0% YoY growth in Q4. If the core engine sputters, Teknova will struggle to hit its top-line targets.
Management's new guidance to become Adjusted EBITDA positive 'by the end of 2027' relies heavily on the success of new commercial investments. The timeline leaves little room for macro or execution missteps.
⚖️ Verdict: ⚪
Neutral. Teknova is surviving the biotech funding winter and executing well on margins and cash flow. However, the deceleration in expected FY26 revenue growth and the flatlining of the core Lab Essentials segment in Q4 temper enthusiasm.
Key Themes
Structural Gross Margin Expansion Holds Firm
A major positive theme in 2025 was the structural shift in gross margin, which stabilized at 32.5% in Q4 (up from 23.0% a year ago). This improvement is being driven by higher Clinical Solutions volume and hard-won manufacturing efficiency gains at the company's new facility. Teknova is proving it has the operational leverage required to scale profitably.
Lab Essentials Growth Hits a Wall
The Lab Essentials segment, which historically acts as the company's 'predictable and growing' foundation, decelerated sharply to 0% YoY growth in Q4 ($6.8M vs $6.8M in 24Q4). This is a stark contrast to the 16% and 12% growth rates seen earlier in 2025. Management needs to clarify whether this was a timing issue, a market slowdown, or an impact from fewer business days in Q4.
Clinical Customer Pipeline Expanding
Despite severe quarter-to-quarter lumpiness, the underlying demand for custom biopharma products is growing. The number of Clinical Solutions customers grew 25% annually in 2025. Management's thesis—that these early-stage biotech customers will scale their purchases exponentially as their novel therapies move from Phase 1 to commercialization—remains the central long-term growth driver.
Pivoting Capital to Commercial Operations
After years of heavy capital expenditure on state-of-the-art manufacturing facilities, management is pivoting investment toward the commercial team. CEO Stephen Gunstream explicitly noted the decision to 'further invest in our commercial capabilities this year.' This explains the targeted $0.4M drop in operating expenses excluding one-time items, which would have been lower had they not increased sales and marketing spend.
Biotech Funding Environment Continues to Dictate the Pace
While management cited 'signs that the biotech funding environment is likely to continue to improve,' the reality is that the recovery is slow. The company's reliance on early-stage biopharma companies—many of whom remain capital constrained—introduces ongoing revenue lumpiness and explains the muted mid-single-digit growth guidance for FY26.
Other KPIs
Stable. The company ended 2025 with $21.3 million in liquidity against gross debt of $13.2 million. Given the FY26 guidance for Free Cash Outflow of less than $10 million, Teknova appears to have roughly two years of runway. This supports management's prior assertions that they do not need to raise equity to fund organic growth.
Accelerating improvement. Adjusted EBITDA loss narrowed significantly from -$3.2M in 24Q4. For the full year, the metric improved to -$6.7M from -$14.5M in 2024, reflecting the impact of higher gross margins and disciplined overall cost controls.
Guidance
Decelerating. The midpoint of $43 million implies 6.1% YoY growth, a slowdown from the 7% growth achieved in FY25. This suggests management is taking a conservative stance on the biotech funding recovery and acknowledges potential drag from the flatlining Lab Essentials business.
Stable. This represents a continuation of recent cash burn trends. While better than the -$13.5M outflow in 2024, it is largely in line with the -$9.8M achieved in 2025. It indicates that the 'increased investment in commercial capabilities' will keep cash burn relatively flat rather than allowing for further aggressive reductions.
Key Questions
Lab Essentials Stagnation
Lab Essentials revenue was perfectly flat in Q4 YoY. Was this a result of fewer shipping days, a deceleration in baseline demand, or a loss of market share?
Commercial Investment ROI
You highlighted a strategic decision to increase investment in commercial capabilities. What specific metrics or early indicators give you the confidence that this increased spend will re-accelerate the top line in 2026 and 2027?
Path to Profitability Timeline
The target for Adjusted EBITDA positivity is now specifically 'by the end of 2027.' What revenue run-rate does your model require to cross that threshold, assuming gross margins remain in the low-to-mid 30s?